HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Reviva Pharmaceuticals (NASDAQ:RVPH) and maintained a $20 price target.
April 22, 2024 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reviva Pharmaceuticals receives a reiterated Buy rating and a maintained $20 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. can positively influence investor sentiment towards RVPH. This endorsement may lead to increased investor confidence and potential upward movement in RVPH's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100